Skip to content
The Nexus
DossierENTITY

PCSK9 protein

Coverage of PCSK9 protein in the Nexus archive.

Earliest in view: May 1 · 08:50 UTCMost recent: Jul 16 · 17:48 UTC
Co-mentioned in this coverage
LDL cholesteroltopic2FDAorganization1Merckorganization1Lipfendratopic1Marty Makaryperson1Amgenorganization1Statinstopic1DNA-based moleculestopic1heart diseasetopic1statinstopic1high cholesteroltopic1
Recent coverage
  • HEALTHJul 16 · 17:48 UTCWDIV CLICKONDETROIT
    FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

    The FDA approved Merck's Lipfendra, the first non-injectable pill to significantly reduce LDL cholesterol in high-risk patients by blocking the PCSK9 protein. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under an accelerated FDA program led by Dr. Marty Makary. It offers an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.

  • HEALTHMay 1 · 08:50 UTCSCIENCE DAILY
    New treatment cuts bad cholesterol by nearly 50% without statins

    Researchers have developed DNA-based molecules that block the PCSK9 protein, reducing LDL cholesterol levels by nearly 50% and offering a statin-free alternative for treating high cholesterol and heart disease.